# Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Severe Sickle Cell Disease

> **NCT04207320** · NA · TERMINATED · sponsor: **University of Chicago** · enrollment: 3 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DEVICE:** αβ+ T-cell depletion with Miltenyi CliniMACS system

## Key facts

- **NCT ID:** NCT04207320
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-07
- **Primary completion:** 2023-05-22
- **Final completion:** 2023-05-22
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study terminated by PI
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04207320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04207320, "Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Severe Sickle Cell Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04207320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*